Press Releases

We’re Delivering the Promise of Healthier Lives.

CURE PHARMACEUTICAL 

Press Releases

We specialize in optimal formulations to achieve targeted release and exposure of medications.​

CURE Pharmaceutical Expands U.S. DEA Approval to Manufacture Pharmaceuticals Using Whole Cannabis Plant

CURE Pharmaceutical Expands U.S. DEA Approval to Manufacture Pharmaceuticals Using Whole Cannabis Plant

OXNARD, Calif., March 12, 2019 (GLOBE NEWSWIRE) — CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, today announced it has broadened its U.S. Drug Enforcement Administration (DEA) license as an authorized manufacturer of Schedule 1 substances to include both cannabis plant extracts and synthetic cannabidiol (CBD). This license allows CURE to take […]

read more
CURE Pharmaceutical Secures U.S. DEA Approval to Manufacture Cannabinoid-based Pharmaceuticals

CURE Pharmaceutical Secures U.S. DEA Approval to Manufacture Cannabinoid-based Pharmaceuticals

OXNARD, Calif., Nov. 26, 2018 (GLOBE NEWSWIRE) — CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, today announced it has secured a new registration with the Drug Enforcement Administration (DEA) as a manufacturer authorized to handle Schedule 1 controlled substances. With this license, CURE will develop and manufacture cannabinoid-based pharmaceutical products using its […]

read more

This press release is a modified version of the official Sleep Club Press Release that can be found here. Please read the official release for more information. This version of the press release does not present any new information or information that is different from that contained in the official press release. It only serves to […]

read more
CURE Pharmaceutical Expands Distribution of CUREfilm Technology with First Licensing Agreement

CURE Pharmaceutical Expands Distribution of CUREfilm Technology with First Licensing Agreement

CURE grants cannabis leader rights to its proprietary drug delivery technology in markets around the world. LOS ANGELES, Sept. 05, 2018 (GLOBE NEWSWIRE) — CURE Pharmaceutical (OTC:CURR), (“CURE”), an innovative drug delivery and development company, today announced that it entered into a multi-year licensing agreement for the first time with a leading international cannabis company. […]

read more
Cure Pharmaceutical Plans to Acquire Cannabinoid-Based Drug Pipeline from Therapix Biosciences Ltd.

Cure Pharmaceutical Plans to Acquire Cannabinoid-Based Drug Pipeline from Therapix Biosciences Ltd.

OXNARD, Calif., July 11, 2018 (GLOBE NEWSWIRE) — CURE Pharmaceutical (OTCQB:CURR), (“CURE”), an innovative drug delivery and development company, announced today that it has signed a term sheet with Therapix Biosciences Ltd. (Nasdaq:TRPX), (“Therapix”), a specialty, clinical-stage pharmaceutical company developing cannabinoid-based treatments, to acquire the non-pain assets of Therapix, subject to the completion of the […]

read more